David Hafler (Yale School of Medicine, CT) considers recent developments in understanding of genetic risk, as well as the roles of regulatory T cells and B cells in multiple sclerosis (MS), and shares his view on what he considers to be the most important therapeutic targets in MS and remaining questions yet to be addressed.
1. To what extent do genetic variants drive the risk of MS? (0:11)
2. What has recent research taught us about the role of regulatory T cells in MS? (1:18)
3. How can these findings be used in the development of new therapies for MS? (2:13)
4. What do you consider the most important breakthrough in MS therapy in the last year? (2:54)
5. What do you consider to be the most urgent unmet need in MS at present? (3:53)
Speaker disclosure: David Hafler serves as a consultant to Compass Therapeutics, EMD Serono, and Merck Sharp & Dohme; is on scientific advisory boards for Genentech, MedImmune, and Mylan Pharmaceuticals; and has received research support/funding from Genentech and Bristol-Myers Squibb.
Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018.
Share this Video
Related Videos In Multiple Sclerosis
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!